STRATA Skin Sciences to Report Second Quarter 2024 Financial Results on August 14, 2024 and Provide Corporate Update
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has announced its plans to report second quarter 2024 financial results on August 14, 2024, after market close. The company will host a conference call at 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.
Interested parties can join the call by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international). A live webcast will also be available. A telephonic replay will be accessible until August 21, 2024, and a webcast replay will be available until February 14, 2025.
STRATA Skin Sciences (NASDAQ: SSKN), un'azienda di tecnologia medica focalizzata sui trattamenti dermatologici, ha annunciato i suoi piani per riportare i risultati finanziari del secondo trimestre 2024 il 14 agosto 2024, dopo la chiusura del mercato. L'azienda ospiterà una conference call alle 16:30 ET dello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale.
Le parti interessate possono partecipare alla chiamata componendo il numero 1-877-270-2148 (nazionale) o 1-412-902-6510 (internazionale). Sarà inoltre disponibile una diretta web. Una registrazione telefonica sarà accessibile fino al 21 agosto 2024, e una registrazione web sarà disponibile fino al 14 febbraio 2025.
STRATA Skin Sciences (NASDAQ: SSKN), una empresa de tecnología médica centrada en tratamientos dermatológicos, ha anunciado sus planes para informar sobre los resultados financieros del segundo trimestre de 2024 el 14 de agosto de 2024, después del cierre del mercado. La empresa llevará a cabo una conferencia telefónica a las 4:30 p.m. ET el mismo día para discutir los resultados y proporcionar una actualización corporativa.
Las partes interesadas pueden unirse a la llamada marcando el 1-877-270-2148 (nacional) o el 1-412-902-6510 (internacional). También habrá disponible una transmisión en vivo. Una grabación telefónica estará accesible hasta el 21 de agosto de 2024, y una grabación de la transmisión estará disponible hasta el 14 de febrero de 2025.
STRATA Skin Sciences (NASDAQ: SSKN)는 피부과 치료에 중점을 둔 의료 기술 회사로, 2024년 8월 14일 오후 4시 30분 ET에 2024년 2분기 재무 결과를 발표할 계획이라고 발표했습니다. 시장 마감 이후 발표된 결과를 논의하고 기업 업데이트를 제공하기 위한 전화 회의를 같은 날 개최할 예정입니다.
관심 있는 당사자는 국내 1-877-270-2148 또는 국제 1-412-902-6510으로 전화하여 회의에 참가할 수 있습니다. 라이브 웹캐스트도 제공됩니다. 전화 녹음은 2024년 8월 21일까지 이용 가능하며, 웹캐스트 녹음은 2025년 2월 14일까지 이용 가능합니다.
STRATA Skin Sciences (NASDAQ: SSKN), une entreprise de technologie médicale axée sur les traitements dermatologiques, a annoncé ses projets de publier les résultats financiers du deuxième trimestre 2024 le 14 août 2024, après la clôture du marché. L'entreprise organisera une conférence téléphonique à 16h30 ET le même jour pour discuter des résultats et fournir une mise à jour d'entreprise.
Les parties intéressées peuvent participer à l'appel en composant le 1-877-270-2148 (national) ou le 1-412-902-6510 (international). Un webinaire en direct sera également disponible. Un enregistrement par téléphone sera accessible jusqu'au 21 août 2024, et un enregistrement du webinaire sera disponible jusqu'au 14 février 2025.
STRATA Skin Sciences (NASDAQ: SSKN), ein Medizintechnikunternehmen, das sich auf dermatologische Behandlungen spezialisiert hat, hat seine Pläne angekündigt, die Finanzergebnisse des zweiten Quartals 2024 am 14. August 2024 nach Börsenschluss zu berichten. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Interessierte Parteien können sich in die Konferenz einwählen, indem sie die Nummer 1-877-270-2148 (national) oder 1-412-902-6510 (international) wählen. Es wird auch ein Live-Webcast verfügbar sein. Eine telefonische Aufzeichnung ist bis zum 21. August 2024 zugänglich, und eine Webcast-Aufzeichnung wird bis zum 14. Februar 2025 verfügbar sein.
- None.
- None.
HORSHAM, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2024 financial results on Wednesday, August 14, 2024 after the market close.
STRATA management will host a conference call at 4:30 p.m. ET on Wednesday, August 14, 2024 to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session.
To listen to the conference call, interested parties within the U.S. should dial 1-877-270-2148 (domestic) or 1-412-902-6510 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the STRATA Skin Sciences, Inc. conference call.
The conference call will also be available through a live webcast that can be accessed at STRATA Skin Sciences 2Q24 Earnings Webcast.
A telephonic replay of the call will be available until August 21, 2024 by dialing 1-877-344-7529 (or 1-412-317-0088 for international callers) and using replay access code 7605445. To access the replay using an international dial-in number, please see here.
A webcast earnings call replay will be available approximately one hour after the live call until February 14, 2025.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
FAQ
When will STRATA Skin Sciences (SSKN) report its Q2 2024 financial results?
How can investors join STRATA Skin Sciences' (SSKN) Q2 2024 earnings call?
Will there be a replay available for STRATA Skin Sciences' (SSKN) Q2 2024 earnings call?